The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC).
M. E. Gore
Consultant or Advisory Role - Bayer
Honoraria - Bayer
R. J. Jones
Research Funding - Bayer
A. Ravaud
Consultant or Advisory Role - Bayer
Honoraria - Bayer
M. Kuczyk
Honoraria - Bayer; GSIC; Pfizer
Expert Testimony - Bayer (U); GSIC (U); Novartis (U); Pfizer (U)
T. Demkow
No relevant relationships to disclose
A. Bearz
No relevant relationships to disclose
N. Laferriere
Employment or Leadership Position - Bayer Schering Pharma (U)
U. P. Strauss
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
C. Porta
Consultant or Advisory Role - BSP; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - BSP; Novartis